No. When reviewing the data, it is important to note that anti-doping organizations (ADOs) do not always report to WADA on statistics from the same period of time. In addition, some organizations have reported on testing at the international level only, while others have reported on both international and national levels.

An Adverse Analytical Finding indicates the presence of prohibited substances or methods in a particular sample. Adverse Analytical Findings should not be confused with adjudicated or sanctioned Anti-Doping Rules Violations (ADRV) for several reasons.

First, these figures may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings may correspond to multiple measurements performed on the same athlete, such as in cases of longitudinal studies in testosterone (i.e., tracking the testosterone level of one athlete over a period of time).
 

In 2005, WADA began the roll out of ADAMS (Anti-Doping Administration & Management System), a web-based database management tool for athletes and ADOS. ADAMS is a platform for result management, administration of TUEs, athlete whereabouts information, and test distribution planning.

With the full adoption of ADAMS by stakeholders, the sporting community will have a transparent means for tracking results, from collection to sanction, while respecting confidentiality. In addition, complete analysis of data will be available, including linking Adverse Analytical Findings to TUEs and sanctioned cases.

As required by the World Anti-Doping Code, anti-doping organizations shall publish, at least annually, a general statistical report of their doping control activities. WADA will publish, at least annually, statistical reports summarizing the information that it receives, ensuring at all times that the privacy of athletes is fully respected.